Vaccines

Coronavirus Update

Rochester Clinical Research is following the ever-changing impact of the Coronavirus on a national level and in our local community. Please review our COVID Reopening Patient Access.

Pneumonia Vaccine

Rochester Clinical Research is currently enrolling generally healthy individuals over 50 years old for a vaccine research study. The study will assess the safety and tolerability of two different dosage levels of study vaccine that may protect against a greater number of strains of pneumococcal disease. The study will last approximately 6 months with two visits to our office and 3 telephone calls.

E. Coli Vaccine

Rochester Clinical Research is currently enrolling individuals over the age of 60 years old, who have had a UTI within the past 5 years for an E. coli vaccine research study. The study will evaluate the effectiveness of a stud vaccine that may protect against E. coli that could cause sepsis.

Chikungunya Vaccine

Rochester Clinical Research is participating in a study evaluating the immune response of a single dose of the study Chikungunya vaccine in healthy adults over the age of 18 years old.

Men’s HPV Vaccine

The purpose of this research study is to determine the efficacy and safety of a 3-dose HPV vaccine in males between the ages of 20- 45. The vaccine aims to prevent HPV infection which are associated with oral cancer. Compensation is available up to $1,300, for those who qualify.

*Compensation for time and travel may be available to those who qualify.